Upcoming Medical Conferences in BartlesvilleSearch Criteria : United States of America Bartlesville
B-Cell Malignancies Tumor Board: Therapeutic Decision Making in Challenging Clinical Scenarios (Jul 17, 2019)
Jul 17, 2019 | CME 1.00 | Bartlesville, Oklahoma
B-Cell Malignancies Tumor Board: Therapeutic Decision Making in Challenging Clinical Scenarios is organized by Creative Educational Concepts (CEC) and will be held on Jul 17, 2019 at Bartlesville, Oklahoma, United States of America. Target Audience : Practitioners involved in the care of patients with B-cell malignancies including hematologists, oncologists, hem/onc residents/fellows, heme specialty NPs, nurses, nurse navigators, PAs, and pharmacists. Accreditation: Medicine (ACCME) CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacy (ACPE) This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-19-006-L01-P). Nursing (ANCC) This activity is designated for 1.0 contact hour. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. Physician Assistants (AAPA) Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Description : This course is designed to prepare the nurse specializing in the care of stroke patients for the certification exam. Objectives : At the conclusion of this application-based activity, participants will be able to: • Analyze the changing paradigm in clinical approaches to management of B-cell malignancies with BTK therapy and the implications for patient care. • Examine key issues in therapy selection, including appropriate sequencing and combination of agents in a range of clinical scenarios based on individual patient factors, as well as disease and treatment status. • Identify strategies to successfully incorporate novel therapies for B-cell malignancies, including the growing range of targeted therapies, into clinical practice. Additional details will be posted as soon as they are available.